Last updated: June 18, 2026
Allergan v. Sandoz (2:09-cv-00097): Litigation Summary, Claims at Issue, and Patent-Strategy Impact
Allergan, Inc. v. Sandoz Inc., docket 2:09-cv-00097 is a U.S. Hatch-Waxman patent infringement dispute tied to Sandoz’s ANDA launch planning against an Allergan branded product. The litigation is located in the Eastern District of Texas (EDTX), a forum commonly used for ANDA Paragraph IV patent cases during that period. The case’s practical effect is to determine (1) which Orange Book-listed patents were asserted and (2) whether Sandoz’s proposed generic marketing date was delayed by court-enforced exclusivity from a successful infringement/invalidity outcome or by a settlement resolving infringement risk.
What this case typically decides in Paragraph IV ANDA litigation
In filings of this type, the court focuses on three tracks that govern exclusivity and launch:
- Infringement of asserted claims in the listed patents (product composition, formulation, manufacturing, and/or method-of-use).
- Validity/unenforceability defenses (anticipation, obviousness, lack of written description/enablement, indefiniteness).
- Regulatory timing consequences, including whether an ANDA can proceed to market and whether marketing is blocked by a statutory injunction under 35 U.S.C. § 271(e)(4).
Given only the docket identifier, the case record elements needed for a precise, claim-level, patent-number-specific summary are not available in this input.
If sufficient case-caption detail and/or the asserted patent list is not provided, a complete and accurate litigation summary cannot be produced under these constraints.
What patents were asserted in Allergan v. Sandoz 2:09-cv-00097?
Actionable answer required: asserted patent numbers, claim(s), and asserting Allergan entity vs. patent assignee.
Under the provided input, those elements cannot be determined.
What is the procedural history in Allergan v. Sandoz 2:09-cv-00097 (EDTX)?
Actionable answer required: complaint date, answer date, claim construction dates, summary judgment/injunction events, trial dates, and the final disposition.
Under the provided input, those elements cannot be determined.
What were the core infringement theories in Allergan v. Sandoz 2:09-cv-00097?
Actionable answer required: whether the asserted claims targeted
- drug substance/composition,
- formulation/dosage form,
- manufacturing process,
- or method-of-use claims.
Under the provided input, those elements cannot be determined.
How did the court rule on validity in Allergan v. Sandoz 2:09-cv-00097?
Actionable answer required: summary judgment outcomes by invalidity ground, claim construction rulings, and any final judgment basis.
Under the provided input, those elements cannot be determined.
Did Allergan and Sandoz reach a settlement in 2:09-cv-00097, and what did it mean for generic entry?
Actionable answer required: settlement agreement terms, triggered launch dates, exclusivity carve-outs, or “at-risk” launch authorization.
Under the provided input, those elements cannot be determined.
What is the Orange Book status linked to this litigation docket?
Actionable answer required: list of Orange Book patents for the relevant NDA, including
- expiration dates,
- pediatric exclusivity extensions,
- regulatory exclusivity,
- and which patents were asserted.
Under the provided input, those elements cannot be determined.
Which generic company designs and manufacturing/IP barriers were litigated?
Actionable answer required: whether Sandoz is the ANDA filer, whether there are co-defendants, and the manufacturing site or contract manufacturer tied to the ANDA ANDAs.
Under the provided input, those elements cannot be determined.
How does Allergan v. Sandoz 2:09-cv-00097 compare with other EDTX Allergan Paragraph IV cases?
Actionable answer required: case-specific patterns such as claim construction outcomes, repeated patent assertions, and typical settlement ranges.
Under the provided input, those elements cannot be determined.
Key Takeaways
No claim-level, patent-level, or outcome-level litigation facts can be stated from the docket identifier alone without risking inaccuracies.
FAQs
- What does a docket-only reference like “2:09-cv-00097” include for Hatch-Waxman context?
- How do claim construction rulings typically affect ANDA design-around efforts in EDTX Paragraph IV cases?
- What outcomes most directly control generic launch timing: infringement verdicts, invalidity rulings, or settlements?
- How does pediatric exclusivity or PTA interact with court outcomes in ANDA patent litigation?
- What settlement terms most often appear in ANDA paragraph IV resolutions affecting market entry?
References
No sources were cited because no case documents, docket-sheet facts, or patent identifiers were provided in the prompt.
